Highlights
In Fuchs endothelial corneal dystrophy, the need for keratoplasty is clinically important but often difficult to predict using examination findings alone.
A 2026 study in Ophthalmology reports that genomic risk profiling, specifically CTG18.1 repeat expansion status combined with a disease-specific polygenic risk score, predicts risk of progression to keratoplasty.
The predictive findings were validated across independent cohorts, supporting external reproducibility rather than a single-cohort signal.
If confirmed in broader practice settings, genetic stratification could improve prognostic counseling, follow-up intensity, and future trial enrichment for FECD.
Why This Study Matters
Fuchs endothelial corneal dystrophy, or FECD, is one of the most common corneal endothelial dystrophies and a leading indication for corneal transplantation in many countries. The disease is characterized by progressive endothelial cell dysfunction, formation of Descemet membrane guttae, and eventual corneal edema with reduced visual quality. Patients may initially report glare, fluctuating morning blur, or reduced contrast sensitivity before developing more persistent visual loss.
The core clinical challenge is heterogeneity. Some patients with FECD remain stable for long periods, while others progress to visually significant corneal decompensation and ultimately require keratoplasty. This uncertainty complicates patient counseling, referral timing, surveillance intervals, and procedural planning. In the current era of endothelial keratoplasty and increasingly precise anterior segment imaging, clinicians still lack a widely adopted prognostic model that reliably forecasts which patients will progress to surgery.
That gap makes genetics attractive. FECD has long been recognized as a disorder with substantial heritable contribution. The intronic CTG trinucleotide repeat expansion in the TCF4 locus, commonly referred to as CTG18.1, is the most established common genetic risk factor for FECD in populations of European ancestry. At the same time, FECD is not a monogenic disease in most patients. Its penetrance and severity likely reflect a combination of repeat expansion biology, additional common risk alleles, age-related susceptibility, and environmental or stochastic influences. A disease-specific polygenic risk score therefore offers a plausible next step beyond single-variant testing.
Proposed Section Structure for Interpreting This Study
For this topic, a clinically useful article is best organized around six questions: the disease burden and unmet prognostic need; the biologic rationale for genomic prediction in FECD; study design and cohorts; the main predictive findings; implications for practice and research; and remaining limitations before clinical implementation. That structure is used below.
Background: FECD as a Prognostic and Surgical Disease
FECD typically presents in mid-to-late adulthood and becomes increasingly prevalent with age. Although slit-lamp examination remains central, disease severity is not always captured by a single sign. Corneal guttae burden, pachymetry, endothelial cell loss, edema, visual symptoms, and lens status all influence management decisions. Moreover, the threshold for surgery has shifted as endothelial keratoplasty techniques such as Descemet membrane endothelial keratoplasty and Descemet stripping automated endothelial keratoplasty have improved outcomes compared with historical full-thickness penetrating keratoplasty.
Even so, timing remains nuanced. Surgery too early may expose a patient to operative risks before meaningful functional decline; surgery too late may prolong disability and complicate postoperative visual recovery, especially if stromal changes have accumulated. Better prognostic tools could therefore have direct clinical value.
The genetic architecture of FECD supports this line of investigation. CTG18.1 repeat expansion in TCF4 is strongly associated with disease susceptibility and severity in multiple studies. Mechanistically, expanded repeats are thought to contribute to toxic RNA-mediated effects, including RNA foci and missplicing, although FECD biology is broader and includes oxidative stress, mitochondrial dysfunction, unfolded protein response signaling, and extracellular matrix abnormalities. A polygenic risk score, by aggregating many common variants of individually modest effect, may capture part of that broader susceptibility landscape.
Study Design and Methods
Liu and colleagues, writing in Ophthalmology in 2026, examined whether genomic risk profiling can predict progression to keratoplasty in FECD. Based on the abstract, the two central genomic components were CTG18.1 expansion status and a FECD-specific polygenic risk score. The key clinical outcome was keratoplasty, a pragmatic and highly relevant endpoint that reflects progression to disease severity warranting corneal transplantation.
The study’s notable methodological strength, as stated in the abstract, is validation across independent cohorts. External validation is essential for any prognostic model, particularly for genetic prediction, because performance can otherwise be inflated by cohort-specific structure, ancestry composition, referral patterns, or local treatment thresholds.
The abstract does not provide all design details needed for full critical appraisal, such as exact cohort sizes, ancestry distribution, genotyping and repeat-expansion assay methods, candidate clinical covariates, model calibration metrics, discrimination statistics, or time-to-event versus cross-sectional analytic strategy. Those specifics will matter when evaluating readiness for clinical use. Still, even at the abstract level, the study appears to move beyond association toward clinically anchored prediction.
Key Findings
Genetic factors predicted keratoplasty risk
The principal finding is that genomic risk profiling predicted keratoplasty risk in FECD. Importantly, the model was not limited to a single known high-impact variant. Rather, it incorporated both CTG18.1 expansion status and a disease-specific polygenic risk score. This matters because it suggests that progression to surgery reflects cumulative genetic burden, not simply the presence or absence of one repeat expansion.
Prediction was validated across independent cohorts
Validation across independent cohorts is arguably the most important translational feature of the paper. Many biomarker studies identify promising predictors in discovery samples but fail when tested elsewhere. Independent-cohort validation indicates that the predictive signal was sufficiently robust to persist beyond the derivation dataset. For clinicians and trialists, this is more persuasive than an isolated association study.
CTG18.1 alone may not be the full prognostic story
CTG18.1 is already the dominant genetic marker in FECD discussions, but this study suggests that adding a FECD-specific polygenic risk score improves prognostic granularity. In practical terms, two patients with clinically similar FECD and even similar CTG18.1 status may differ in cumulative inherited risk for progression. A polygenic framework may therefore help explain part of the variability seen in clinic.
The endpoint is clinically meaningful
Using keratoplasty as the endpoint increases clinical interpretability. Unlike subtle imaging progression or isolated pachymetric change, keratoplasty is a hard outcome that reflects disease burden, symptoms, physician judgment, and surgical decision-making. Although surgical thresholds can vary by surgeon and health system, this endpoint remains highly relevant to patients.
What the abstract does not tell us
The abstract summary provided here does not include effect sizes, confidence intervals, area under the receiver operating characteristic curve, net reclassification improvement, calibration slope, or subgroup analyses. It also does not specify whether the genomic predictors retained significance after adjustment for baseline clinical severity, age, sex, or ocular comorbidity. These missing data do not negate the study’s importance, but they limit how confidently clinicians can judge immediate applicability. The full paper will be necessary to determine whether the model adds enough incremental value beyond standard ophthalmic assessment to justify testing in routine care.
Clinical Interpretation
This study is best viewed as a step toward precision prognostication in corneal disease. If the reported findings are confirmed and refined, there are several plausible clinical applications.
First, genomic profiling could improve counseling at diagnosis. Patients with FECD often ask whether and when they may need surgery. Current answers are necessarily approximate. A validated genetic risk estimate could complement baseline examination, imaging, and symptom assessment to provide more individualized prognostic conversations.
Second, genetics could help tailor follow-up intensity. Patients at low predicted risk of near-term progression might need less frequent specialist review, whereas those at high genomic risk could be monitored more closely for functional decline, edema, or cataract surgery planning. This is especially relevant because cataract extraction in FECD requires nuanced decision-making about the possibility of combined or staged endothelial keratoplasty.
Third, genetic enrichment could strengthen clinical trials. FECD therapeutic development, including approaches targeting repeat-expansion biology or endothelial preservation, would benefit from enrolling patients at higher risk of clinically meaningful progression. A genomic risk tool may help identify those most likely to reach endpoints such as surgery, edema progression, or visual decline within feasible trial timelines.
Fourth, this work strengthens the biologic case for FECD as a genetically stratifiable disease rather than a uniform age-related degeneration. That matters for both drug development and patient selection in future interventional studies.
Limitations and Cautions
Despite the promise, several caveats deserve emphasis.
One, keratoplasty is a clinically meaningful endpoint but not a purely biologic one. The decision to operate depends on symptoms, surgeon preference, local access to endothelial keratoplasty, patient expectations, and coexisting cataract or ocular disease. A patient may have severe FECD but not undergo surgery for nonbiologic reasons, while another may proceed earlier in a setting with ready surgical access.
Two, the portability of genetic prediction across ancestries is a major issue. Polygenic risk scores often perform best in ancestry groups resembling the discovery population and degrade with increasing genetic distance. FECD genetics, especially around TCF4 repeat expansion and common variant architecture, may not generalize evenly across populations. External validation beyond European-ancestry cohorts will be essential before broad implementation.
Three, a useful clinical prediction model must demonstrate added value over established clinical data. For FECD, this includes slit-lamp phenotype, corneal thickness, tomography or Scheimpflug-derived edema features, endothelial cell metrics where available, symptom burden, and lens status. Genetic prediction is most compelling when it materially improves discrimination or reclassification beyond these routine measures.
Four, implementation logistics matter. CTG18.1 testing is more specialized than standard SNP-based genotyping, and combined genomic workflows would need quality assurance, reporting standards, informed consent processes, and practical interpretation for ophthalmologists who are not geneticists.
Five, ethical considerations should not be overlooked. Prognostic genetic testing can affect anxiety, insurability perceptions, and family communication. In a disease with treatable late-stage manifestations but uncertain timing of progression, the framing of risk estimates will need careful attention.
Mechanistic Relevance
The finding that CTG18.1 and a FECD-specific polygenic score together predict surgery risk is biologically coherent. CTG18.1 likely captures a major component of RNA toxicity-driven susceptibility linked to TCF4. A polygenic score may incorporate additional pathways influencing endothelial resilience, extracellular matrix remodeling, cellular stress handling, and age-related vulnerability. In other words, the combined score may better reflect both a dominant disease mechanism and the broader genetic background that modulates penetrance and progression.
This multi-layered model mirrors the current understanding of many common ophthalmic diseases, where a high-impact locus explains substantial risk but not the full clinical course. The result is especially interesting for FECD because disease severity varies widely even among patients sharing key genetic features.
Implications for Current Practice
The study is unlikely to change routine FECD management immediately on the basis of the abstract alone. However, it does suggest several near-term implications for clinicians and researchers.
For cornea specialists, the main takeaway is that prognosis in FECD may soon become more quantitative and genetics-informed. For comprehensive ophthalmologists, the study reinforces that FECD progression is not solely an examination-based phenomenon and that genetic architecture may eventually shape referral and surveillance decisions. For academic centers, it supports development of integrated FECD registries linking phenotype, imaging, surgery, and genomics.
At present, the best use of this evidence is probably in research settings or specialized clinics with access to genetic testing and longitudinal phenotyping. Before widespread adoption, clinicians will need the full model details, its absolute risk estimates, performance compared with clinical-only models, and evidence of utility across diverse populations and health systems.
Conclusion
Liu and colleagues provide an important advance in FECD prognostication by showing that genomic risk profiling, combining CTG18.1 expansion status with a FECD-specific polygenic risk score, predicts progression to keratoplasty and does so across independent cohorts. The work is clinically relevant because keratoplasty is a hard, patient-centered endpoint and because unpredictability of progression remains a major problem in FECD care.
The study does not yet establish that all patients with FECD should undergo genetic testing. But it does move the field meaningfully closer to precision risk stratification, with potential applications in counseling, surveillance, and trial design. The next questions are practical and important: how much prediction improves beyond standard clinical assessment, whether performance is maintained across ancestries and care settings, and how best to deliver genomic prognostic information in ways that benefit patients.
If those hurdles are cleared, FECD may become one of the first anterior segment disorders in which combined monogenic and polygenic risk information informs real-world management.
Funding and Trial Registration
The provided citation and abstract summary do not include funding details or a ClinicalTrials.gov registration number. No trial registration information is available from the material supplied.
References
1. Liu S, Szabo A, Zarouchlioti C, Bhattacharyya N, Nguyen Q, Costa MA, Luben RN, Dudakova L, Skalicka P, Horak M, Khawaja AP, Pontikos N, Muthusamy K, Tuft SJ, Liskova P, Davidson AE. Genetic Prediction of Keratoplasty in Fuchs Endothelial Corneal Dystrophy. Ophthalmology. 2026-05-24. PMID: 42184904. Available at: https://pubmed.ncbi.nlm.nih.gov/42184904/
2. Matthaei M, Hribek A, Clahsen T, Bachmann BO, Cursiefen C, Jun AS. Fuchs endothelial corneal dystrophy: clinical, genetic, pathophysiologic, and therapeutic aspects. Annu Rev Vis Sci. 2019;5:151-175.
3. Wieben ED, Aleff RA, Tosakulwong N, Butz ML, Highsmith WE, Edwards AO, Baratz KH. A common trinucleotide repeat expansion within the transcription factor 4 gene predicts Fuchs corneal dystrophy. PLoS One. 2012;7(11):e49083.
4. Mootha VV, Hussain I, Cunnusamy K, Graham E, Gong X, Neelam S, Xing C, Bafna V, Petroll WM, Karamichos D. TCF4 triplet repeat expansion and nuclear RNA foci in Fuchs’ endothelial corneal dystrophy. Invest Ophthalmol Vis Sci. 2015;56(3):2003-2011.
5. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern guidelines: Corneal Ectasia and Corneal Disorders resources relevant to endothelial disease management. San Francisco, CA: American Academy of Ophthalmology. Current online guidance should be consulted for up-to-date surgical management recommendations.
